1、根据2024年年报，公司海外营收占比为51.63%，受益于人民币贬值。 来源：新浪证券-红岸工作室 11月24日，中力股份涨0.74%，成交额4755.94万元，换手率2.53%，总市值147.05亿元。 异动分析 人民币贬值受益+机器人概念+智能物流+注册制次新股+新股与次新股 主力持仓 主力轻度控盘，筹码分布较为分散，主力成交额3644.54万，占总成交额的14%。 技术面：筹码平均交易成本为40.61元 2、根据公司招股说明书：公司自成立以来专注于电动叉车等机动工业车辆的技术研发与产品创新。在 机动工业车辆现有生产技术的基础上，结合行业发展趋势和国内外市场需求，公司以绿色化、数字化、 智能化作为发展方向，充分利用多年技术积累，采用独创的"正向研发" 模式，以客户需求为导向，从 产品外形、功能设计出发，不断开发适应市场需求的产品、工艺与技术，历经多年积淀研发出小金刚、 油改电叉车、搬马机器人等多款具有里程碑意义的产品。公司积极发展和布局移动搬运机器人业务， 2020 年推出具备自动化程度高、灵活性强、安全性好等优势的搬马机器人系列产品，有效减少无效搬 运，降低移动搬运机器人应用门槛。 3、2025年1 ...

资料显示，安乃达驱动技术(上海)股份有限公司位于上海市闵行区光中路133弄19号A座1-2层，成立日 期2011年9月6日，上市日期2024年7月3日，公司主营业务涉及电动两轮车电驱动系统研发、生产及销 售。主营业务收入构成为：轮毂电机82.50%，中置电机10.17%，控制器及其他6.79%，其他(补 充)0.54%。 安乃达所属申万行业为：电力设备-电机Ⅱ-电机Ⅲ。所属概念板块包括：次新股、融资融券、专精特 新、小盘、机器人概念等。 截至9月30日，安乃达股东户数1.29万，较上期增加4.89%；人均流通股3399股，较上期增加44.64%。 2025年1月-9月，安乃达实现营业收入15.97亿元，同比增长34.10%；归母净利润9605.65万元，同比增长 13.05%。 分红方面，安乃达A股上市后累计派现1.45亿元。 11月21日，安乃达盘中下跌2.08%，截至09:54，报36.72元/股，成交1351.94万元，换手率0.83%，总市 值42.75亿元。 资金流向方面，主力资金净流出91.59万元，大单买入181.08万元，占比13.39%，卖出272.67万元，占比 20.17%。 安乃达今年 ...

11月20日，巍华新材盘中下跌2.00%，截至14:03，报17.60元/股，成交4587.42万元，换手率1.40%，总 市值60.78亿元。 资金流向方面，主力资金净流出771.82万元，特大单买入0.00元，占比0.00%，卖出370.40万元，占比 8.07%；大单买入657.84万元，占比14.34%，卖出1059.27万元，占比23.09%。 责任编辑：小浪快报 资料显示，浙江巍华新材料股份有限公司位于浙江省杭州湾上虞经济技术开发区北塘东路8号，成立日 期2013年10月12日，上市日期2024年8月14日，公司主营业务涉及氯甲苯和三氟甲基苯系列产品研发、 生产和销售。主营业务收入构成为：三氟甲基苯系列79.35%，氯甲苯系列19.71%，其他(补充)0.95%。 巍华新材所属申万行业为：基础化工-化学制品-氟化工。所属概念板块包括：小盘、氟化工、新材料、 融资融券、次新股等。 截至9月30日，巍华新材股东户数1.99万，较上期减少1.68%；人均流通股9287股，较上期增加1.71%。 2025年1月-9月，巍华新材实现营业收入6.60亿元，同比减少15.18%；归母净利润1.09亿元，同比减少 ...

Core Viewpoint - The stock of Aidi Te (爱迪特) has experienced a decline of 2.15% on November 20, with a current price of 43.66 CNY per share, reflecting a market capitalization of 4.653 billion CNY. The company has shown a year-to-date stock price increase of 6.39%, but has faced recent declines over various trading periods [1]. Financial Performance - For the period from January to September 2025, Aidi Te achieved a revenue of 747 million CNY, representing a year-on-year growth of 16.44%. The net profit attributable to shareholders was 142 million CNY, marking a 27.40% increase compared to the previous year [2]. Shareholder Information - As of September 30, Aidi Te had 9,851 shareholders, an increase of 4.66% from the previous period. The average number of circulating shares per shareholder decreased by 4.46% to 7,310 shares [2]. Dividend Distribution - Aidi Te has cumulatively distributed dividends amounting to 49.476 million CNY since its A-share listing [3]. Business Overview - Aidi Te, established on March 15, 2007, is located in Qinhuangdao, Hebei Province. The company specializes in the research, production, and sales of zirconia ceramic blocks and other dental restoration materials. The revenue composition includes 73.74% from dental restoration materials, 19.80% from digital dental equipment, and 6.46% from other products and services [1].

资料显示，苏州天脉导热科技股份有限公司位于苏州市吴中区甪直镇汇凯路68号，成立日期2007年7月 25日，上市日期2024年10月24日，公司主营业务涉及导热散热材料及元器件的研发、生产及销售。主营 业务收入构成为：热管理材料及器件98.37%，其他1.63%。 苏州天脉所属申万行业为：电子-消费电子-消费电子零部件及组装。所属概念板块包括：宁德时代概 念、高派息、融资融券、中盘、次新股等。 截至9月30日，苏州天脉股东户数1.08万，较上期增加6.39%；人均流通股2407股，较上期减少6.00%。 2025年1月-9月，苏州天脉实现营业收入8.18亿元，同比增长18.42%；归母净利润1.43亿元，同比增长 1.54%。 11月20日，苏州天脉盘中下跌2.07%，截至13:16，报165.99元/股，成交1.41亿元，换手率1.59%，总市 值192.02亿元。 资金流向方面，主力资金净流出166.27万元，特大单买入1596.87万元，占比11.31%，卖出1637.93万 元，占比11.60%；大单买入2709.65万元，占比19.19%，卖出2834.85万元，占比20.08%。 苏州天脉今年以来股 ...

Core Viewpoint - The stock of Gangdi Technology has experienced a decline in price and performance metrics, indicating potential challenges in the company's financial health and market position [1][2]. Group 1: Stock Performance - As of November 20, Gangdi Technology's stock price decreased by 2.09%, trading at 68.88 CNY per share, with a market capitalization of 3.835 billion CNY [1]. - Year-to-date, the stock has dropped by 16.49%, with a 3.37% decline over the last five trading days, 8.22% over the last 20 days, and 13.23% over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock trading board) once this year, with the most recent appearance on July 22, where it recorded a net buy of -1.9212 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Gangdi Technology reported a revenue of 361 million CNY, reflecting a year-on-year decrease of 3.30%, and a net profit attributable to shareholders of 43.3869 million CNY, down 25.24% year-on-year [2]. - The company has distributed a total of 55.68 million CNY in dividends since its A-share listing [3]. Group 3: Shareholder and Market Information - As of November 10, the number of shareholders for Gangdi Technology increased to 8,646, a rise of 3.35%, with an average of 2,950 circulating shares per shareholder, up 77.33% [2]. - The company operates within the mechanical equipment sector, specifically in automation equipment and industrial control devices, and is associated with concepts such as new industrialization and Industry 4.0 [2].

Core Viewpoint - The stock of Xiaofang Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 4.826 billion yuan, while the company has shown a year-to-date stock price increase of 16.11% [1] Group 1: Stock Performance - As of November 19, Xiaofang Pharmaceutical's stock price is 30.06 yuan per share, with a trading volume of 24.9066 million yuan and a turnover rate of 1.51% [1] - The stock has seen a decline of 6.12% over the last five trading days, 7.90% over the last 20 days, and 16.50% over the last 60 days [1] - The company has appeared on the "龙虎榜" (a stock trading list) eight times this year, with the most recent appearance on August 4, where it recorded a net buy of 3.9196 million yuan [1] Group 2: Financial Performance - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, representing a year-on-year growth of 8.17%, and a net profit attributable to shareholders of 170 million yuan, up 5.09% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 353 million yuan [3] Group 3: Shareholder Information - As of November 10, the number of shareholders of Xiaofang Pharmaceutical is 13,700, an increase of 2.88% from the previous period, with an average of 3,956 circulating shares per shareholder, a decrease of 2.80% [2] - The ninth largest circulating shareholder is Guangfa Multi-Dimensional Emerging Stock (003745), holding 753,100 shares as a new shareholder, while several funds have exited the top ten circulating shareholders [3] Group 4: Business Overview - Xiaofang Pharmaceutical, established on August 12, 1993, is located in Fengxian District, Shanghai, and specializes in the research, production, and sales of external-use medications [1] - The company's main business revenue composition includes digestive medications (51.05%), skin medications (39.79%), and ear, nose, and throat medications (9.08%) [1]

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a year-to-date increase of 28.73% but a recent decline of 9.40% over the past five trading days, indicating volatility in investor sentiment and market conditions [1]. Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1]. - The company was listed on September 3, 2024, and operates primarily in the medical biology sector, focusing on medical research outsourcing [1]. Financial Performance - As of September 30, 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.79 million yuan, reflecting a significant decline of 111.14% compared to the previous period [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3].

11月18日，太力科技盘中下跌2.01%，截至14:19，报38.56元/股，成交2115.60万元，换手率2.36%，总 市值41.75亿元。 资金流向方面，主力资金净流出3.75万元，大单买入186.37万元，占比8.81%，卖出190.12万元，占比 8.99%。 责任编辑：小浪快报 太力科技所属申万行业为：轻工制造-家居用品-其他家居用品。所属概念板块包括：户外露营、小盘、 次新股、跨境电商、电子商务等。 截至9月30日，太力科技股东户数1.36万，较上期减少16.71%；人均流通股1703股，较上期增加 20.06%。2025年1月-9月，太力科技实现营业收入8.22亿元，同比增长6.98%；归母净利润5314.73万元， 同比减少20.68%。 分红方面，太力科技A股上市后累计派现2707.00万元。 机构持仓方面，截止2025年9月30日，太力科技十大流通股东中，交银瑞思混合(LOF)（501092）位居 第七大流通股东，持股30.00万股，为新进股东。 太力科技今年以来股价跌28.66%，近5个交易日跌1.76%，近20日跌1.96%，近60日跌15.66%。 今年以来太力科技已经3次登上龙虎 ...

Core Viewpoint - Yinos's stock price has experienced fluctuations, with a year-to-date increase of 32.48% but a recent decline of 7.04% over the past five trading days [1] Group 1: Stock Performance - As of November 18, Yinos's stock price was 46.62 CNY per share, with a market capitalization of 6.572 billion CNY [1] - The stock has seen a trading volume of 16.86 million CNY and a turnover rate of 0.39% [1] - The stock's performance over various periods includes a 11.13% increase over the last 20 days and a 6.17% increase over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Yinos reported a revenue of 571 million CNY, reflecting a year-on-year decrease of 35.33% [2] - The company recorded a net profit attributable to shareholders of -14.79 million CNY, a decline of 111.14% year-on-year [2] - Cumulative cash dividends paid since the A-share listing amount to 45.11 million CNY [2] Group 3: Shareholder Information - As of September 30, 2025, the number of Yinos's shareholders was 4,849, a decrease of 9.97% from the previous period [2] - The average number of circulating shares per shareholder increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten shareholders list [2]